{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T08:42:49Z","timestamp":1788856969031,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00417-023-06013-4","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T19:43:07Z","timestamp":1677008587000},"page":"2375-2382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Early response to intravenous methylprednisolone therapy for restrictive myopathy in patients with thyroid eye disease"],"prefix":"10.1007","volume":"261","author":[{"given":"Jae Ho","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Woong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Ah","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Duck","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4228-6556","authenticated-orcid":false,"given":"Kyung In","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,21]]},"reference":[{"key":"6013_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/OPX.0b013e3181ce5702","volume":"87","author":"A Kozaki","year":"2010","unstructured":"Kozaki A, Inoue R, Komoto N, Maeda T, Inoue Y, Inoue T, Ayaki M (2010) Proptosis in dysthyroid ophthalmopathy: a case series of 10,931 Japanese cases. Optom Vis Sci: Off Publ Am Acad Optom 87:200\u2013204. https:\/\/doi.org\/10.1097\/OPX.0b013e3181ce5702","journal-title":"Optom Vis Sci: Off Publ Am Acad Optom"},{"key":"6013_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2169\/internalmedicine.53.1518","volume":"53","author":"Y Hiromatsu","year":"2014","unstructured":"Hiromatsu Y, Eguchi H, Tani J, Kasaoka M, Teshima Y (2014) Graves\u2019 ophthalmopathy: epidemiology and natural history. Intern Med 53:353\u2013360. https:\/\/doi.org\/10.2169\/internalmedicine.53.1518","journal-title":"Intern Med"},{"key":"6013_CR3","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/s0002-9394(14)70585-9","volume":"121","author":"GB Bartley","year":"1996","unstructured":"Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, Gorman CA (1996) The treatment of graves\u2019 ophthalmopathy in an incidence cohort. Am J Ophthalmol 121:200\u2013206. https:\/\/doi.org\/10.1016\/s0002-9394(14)70585-9","journal-title":"Am J Ophthalmol"},{"key":"6013_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1210\/jc.2012-3119","volume":"98","author":"KA Ponto","year":"2013","unstructured":"Ponto KA, Merkesdal S, Hommel G, Pitz S, Pfeiffer N, Kahaly GJ (2013) Public health relevance of Graves\u2019 orbitopathy. J Clin Endocrinol Metab 98:145\u2013152. https:\/\/doi.org\/10.1210\/jc.2012-3119","journal-title":"J Clin Endocrinol Metab"},{"key":"6013_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/ICU.0b013e32827038f2","volume":"18","author":"EO Schotthoefer","year":"2007","unstructured":"Schotthoefer EO, Wallace DK (2007) Strabismus associated with thyroid eye disease. Curr Opin Ophthalmol 18:361\u2013365. https:\/\/doi.org\/10.1097\/ICU.0b013e32827038f2","journal-title":"Curr Opin Ophthalmol"},{"key":"6013_CR6","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS (2010) Graves\u2019 ophthalmopathy. N Engl J Med 362:726\u2013738. https:\/\/doi.org\/10.1056\/NEJMra0905750","journal-title":"N Engl J Med"},{"key":"6013_CR7","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ophtha.2011.07.011","volume":"119","author":"PJ Dolman","year":"2012","unstructured":"Dolman PJ, Cahill K, Czyz CN, Douglas RS, Elner VM, Feldon S, Kazim M, Lucarelli M, Sivak-Collcott J, Stacey AW, Strianese D, Uddin J (2012) Reliability of estimating ductions in thyroid eye disease: an International Thyroid Eye Disease Society multicenter study. Ophthalmology 119:382\u2013389. https:\/\/doi.org\/10.1016\/j.ophtha.2011.07.011","journal-title":"Ophthalmology"},{"key":"6013_CR8","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1056\/NEJMcp0801880","volume":"358","author":"GA Brent","year":"2008","unstructured":"Brent GA (2008) Clinical practice. Graves\u2019 disease. N Engl J Med 358:2594\u20132605. https:\/\/doi.org\/10.1056\/NEJMcp0801880","journal-title":"N Engl J Med"},{"key":"6013_CR9","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMcp0806317","volume":"360","author":"L Bartalena","year":"2009","unstructured":"Bartalena L, Tanda ML (2009) Clinical practice. Graves\u2019 ophthalmopathy. N Engl J Med 360:994\u20131001. https:\/\/doi.org\/10.1056\/NEJMcp0806317","journal-title":"N Engl J Med"},{"key":"6013_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, European Group on Graves O (2016) The 2016 European Thyroid Association\/European Group on Graves\u2019 orbitopathy guidelines for the management of Graves\u2019 orbitopathy. Eur Thyroid J 5:9\u201326. https:\/\/doi.org\/10.1159\/000443828","journal-title":"Eur Thyroid J"},{"key":"6013_CR11","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1210\/jc.2005-0148","volume":"90","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ, Pitz S, Hommel G, Dittmar M (2005) Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy. J Clin Endocrinol Metab 90:5234\u20135240. https:\/\/doi.org\/10.1210\/jc.2005-0148","journal-title":"J Clin Endocrinol Metab"},{"key":"6013_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy. Clin Endocrinol 47:9\u201314. https:\/\/doi.org\/10.1046\/j.1365-2265.1997.2331047.x","journal-title":"Clin Endocrinol"},{"key":"6013_CR13","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1210\/jc.2005-2813","volume":"91","author":"AK Eckstein","year":"2006","unstructured":"Eckstein AK, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves\u2019 ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91:3464\u20133470. https:\/\/doi.org\/10.1210\/jc.2005-2813","journal-title":"J Clin Endocrinol Metab"},{"key":"6013_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/IOP.0b013e3181e9a063","volume":"27","author":"LR Dagi","year":"2011","unstructured":"Dagi LR, Zoumalan CI, Konrad H, Trokel SL, Kazim M (2011) Correlation between extraocular muscle size and motility restriction in thyroid eye disease. Ophthalmic Plast Reconstr Surg 27:102\u2013110. https:\/\/doi.org\/10.1097\/IOP.0b013e3181e9a063","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"6013_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/s0161-6420(92)31931-1","volume":"99","author":"TJ Sullivan","year":"1992","unstructured":"Sullivan TJ, Kraft SP, Burack C, O\u2019Reilly C (1992) A functional scoring method for the field of binocular single vision. Ophthalmology 99:575\u2013581. https:\/\/doi.org\/10.1016\/s0161-6420(92)31931-1","journal-title":"Ophthalmology"},{"issue":"Pt 6","key":"6013_CR16","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/eye.1992.141","volume":"6","author":"GW Aylward","year":"1992","unstructured":"Aylward GW, McCarry B, Kousoulides L, Lee JP, Fells P (1992) A scoring method for Hess charts. Eye (Lond) 6(Pt 6):659\u2013661. https:\/\/doi.org\/10.1038\/eye.1992.141","journal-title":"Eye (Lond)"},{"key":"6013_CR17","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.2214\/ajr.170.4.9530066","volume":"170","author":"A Ozgen","year":"1998","unstructured":"Ozgen A, Ariyurek M (1998) Normative measurements of orbital structures using CT. AJR Am J Roentgenol 170:1093\u20131096. https:\/\/doi.org\/10.2214\/ajr.170.4.9530066","journal-title":"AJR Am J Roentgenol"},{"key":"6013_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/BF03343835","volume":"24","author":"PE Macchia","year":"2001","unstructured":"Macchia PE, Bagattini M, Lupoli G, Vitale M, Vitale G, Fenzi G (2001) High-dose intravenous corticosteroid therapy for Graves\u2019 ophthalmopathy. J Endocrinol Invest 24:152\u2013158. https:\/\/doi.org\/10.1007\/BF03343835","journal-title":"J Endocrinol Invest"},{"key":"6013_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1530\/EJE-07-0558","volume":"158","author":"RJ van Geest","year":"2008","unstructured":"van Geest RJ, Sasim IV, Koppeschaar HP, Kalmann R, Stravers SN, Bijlsma WR, Mourits MP (2008) Methylprednisolone pulse therapy for patients with moderately severe Graves\u2019 orbitopathy: a prospective, randomized, placebo-controlled study. Eur J Endocrinol 158:229\u2013237. https:\/\/doi.org\/10.1530\/EJE-07-0558","journal-title":"Eur J Endocrinol"},{"key":"6013_CR20","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1210\/jc.2012-2389","volume":"97","author":"L Bartalena","year":"2012","unstructured":"Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Veronesi G, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi M, Curro N, Boschi A, Bernard M, von Arx G, European Group on Graves O (2012) Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy. J Clin Endocrinol Metab 97:4454\u20134463. https:\/\/doi.org\/10.1210\/jc.2012-2389","journal-title":"J Clin Endocrinol Metab"},{"key":"6013_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11926-006-0055-x","volume":"8","author":"TE Quan","year":"2006","unstructured":"Quan TE, Cowper SE, Bucala R (2006) The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep 8:145\u2013150. https:\/\/doi.org\/10.1007\/s11926-006-0055-x","journal-title":"Curr Rheumatol Rep"},{"key":"6013_CR22","doi-asserted-by":"publisher","first-page":"7276","DOI":"10.1038\/s41598-018-25370-3","volume":"8","author":"CC Tsai","year":"2018","unstructured":"Tsai CC, Wu SB, Kau HC, Wei YH (2018) Essential role of connective tissue growth factor (CTGF) in transforming growth factor-beta1 (TGF-beta1)-induced myofibroblast transdifferentiation from Graves\u2019 orbital fibroblasts. Sci Rep 8:7276. https:\/\/doi.org\/10.1038\/s41598-018-25370-3","journal-title":"Sci Rep"},{"key":"6013_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1023\/a:1021412601538","volume":"26","author":"FQ Wen","year":"2002","unstructured":"Wen FQ, Kohyama T, Sk\u00f6ld CM, Zhu YK, Liu X, Romberger DJ, Stoner J, Rennard SI (2002) Glucocorticoids modulate TGF-beta production. Inflammation 26:279\u2013290. https:\/\/doi.org\/10.1023\/a:1021412601538","journal-title":"Inflammation"},{"key":"6013_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3389\/fphar.2019.00162","volume":"10","author":"SM Yun","year":"2019","unstructured":"Yun SM, Kim SH, Kim EH (2019) The molecular mechanism of transforming growth factor-\u03b2 signaling for intestinal fibrosis: a mini-review. Front Pharmacol 10:162. https:\/\/doi.org\/10.3389\/fphar.2019.00162","journal-title":"Front Pharmacol"},{"key":"6013_CR25","doi-asserted-by":"publisher","first-page":"348","DOI":"10.5603\/EP.2014.0048","volume":"65","author":"D Kajdaniuk","year":"2014","unstructured":"Kajdaniuk D, Marek B, Niedziolka-Zielonka D, Foltyn W, Nowak M, Sieminska L, Borgiel-Marek H, Glogowska-Szelag J, Ostrowska Z, Drozdz L, Kos-Kudla B (2014) Transforming growth factor beta1 (TGFbeta1) and vascular endothelial growth factor (VEGF) in the blood of healthy people and patients with Graves\u2019 orbitopathy\u2013a new mechanism of glucocorticoids action? Endokrynol Pol 65:348\u2013356. https:\/\/doi.org\/10.5603\/EP.2014.0048","journal-title":"Endokrynol Pol"},{"key":"6013_CR26","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1507\/endocrj.EJ16-0165","volume":"63","author":"JW Kim","year":"2016","unstructured":"Kim JW, Woo YJ, Yoon JS (2016) Is modified clinical activity score an accurate indicator of diplopia progression in Graves\u2019 orbitopathy patients? Endocr J 63:1133\u20131140. https:\/\/doi.org\/10.1507\/endocrj.EJ16-0165","journal-title":"Endocr J"},{"key":"6013_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/iop.0000000000001942","author":"NM I\u00f1iguez-Ariza","year":"2021","unstructured":"I\u00f1iguez-Ariza NM, Sharma A, Garrity JA, Stan MN (2021) The \u201cQuiet TED\u201d-a special subgroup of thyroid eye disease. Ophthalmic Plast Reconstr Surg. https:\/\/doi.org\/10.1097\/iop.0000000000001942","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"6013_CR28","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.ajo.2014.02.044","volume":"157","author":"PN Shams","year":"2014","unstructured":"Shams PN, Ma R, Pickles T, Rootman J, Dolman PJ (2014) Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease. Am J Ophthalmol 157:1299\u20131305. https:\/\/doi.org\/10.1016\/j.ajo.2014.02.044","journal-title":"Am J Ophthalmol"},{"key":"6013_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1210\/jc.2003-030809","volume":"89","author":"MF Prummel","year":"2004","unstructured":"Prummel MF, Terwee CB, Gerding MN, Baldeschi L, Mourits MP, Blank L, Dekker FW, Wiersinga WM (2004) A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab 89:15\u201320. https:\/\/doi.org\/10.1210\/jc.2003-030809","journal-title":"J Clin Endocrinol Metab"},{"key":"6013_CR30","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/0140-6736(93)92001-a","volume":"342","author":"MF Prummel","year":"1993","unstructured":"Prummel MF, Mourits MP, Blank L, Berghout A, Koornneef L, Wiersinga WM (1993) Randomized double-blind trial of prednisone versus radiotherapy in Graves\u2019 ophthalmopathy. Lancet (London, England) 342:949\u2013954. https:\/\/doi.org\/10.1016\/0140-6736(93)92001-a","journal-title":"Lancet (London, England)"},{"key":"6013_CR31","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/s0140-6736(00)02165-6","volume":"355","author":"MP Mourits","year":"2000","unstructured":"Mourits MP, van Kempen-Harteveld ML, Garc\u00eda MBG, Koppeschaar HPF, Tick L, Terwee CB (2000) Radiotherapy for Graves\u2019 orbitopathy: randomised placebo-controlled study. Lancet 355:1505\u20131509. https:\/\/doi.org\/10.1016\/s0140-6736(00)02165-6","journal-title":"Lancet"},{"key":"6013_CR32","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s00417-016-3280-7","volume":"254","author":"JW Kim","year":"2016","unstructured":"Kim JW, Han SH, Son BJ, Rim TH, Keum KC, Yoon JS (2016) Efficacy of combined orbital radiation and systemic steroids in the management of Graves\u2019 orbitopathy. Graefes Arch Clin Exp Ophthalmol 254:991\u2013998. https:\/\/doi.org\/10.1007\/s00417-016-3280-7","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6013_CR33","doi-asserted-by":"publisher","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","volume":"170","author":"J Pritchard","year":"2003","unstructured":"Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ (2003) Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol (Baltimore, Md: 1950) 170:6348\u20136354. https:\/\/doi.org\/10.4049\/jimmunol.170.12.6348","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"key":"6013_CR34","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1210\/endo-119-2-940","volume":"119","author":"D Tramontano","year":"1986","unstructured":"Tramontano D, Cushing GW, Moses AC, Ingbar SH (1986) Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves\u2019-IgG. Endocrinology 119:940\u2013942. https:\/\/doi.org\/10.1210\/endo-119-2-940","journal-title":"Endocrinology"},{"key":"6013_CR35","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1096\/fj.201901719RR","volume":"34","author":"DM Hernandez","year":"2020","unstructured":"Hernandez DM, Kang JH, Choudhury M, Andrianifahanana M, Yin X, Limper AH, Leof EB (2020) IPF pathogenesis is dependent upon TGFbeta induction of IGF-1. FASEB J 34:5363\u20135388. https:\/\/doi.org\/10.1096\/fj.201901719RR","journal-title":"FASEB J"},{"key":"6013_CR36","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marin\u00f2 M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ (2020) Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 382:341\u2013352. https:\/\/doi.org\/10.1056\/NEJMoa1910434","journal-title":"N Engl J Med"},{"key":"6013_CR37","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1001\/jamaophthalmol.2021.6284","volume":"140","author":"RS Douglas","year":"2022","unstructured":"Douglas RS, Dailey R, Subramanian PS, Barbesino G, Ugradar S, Batten R, Qadeer RA, Cameron C (2022) Proptosis and diplopia response with teprotumumab and placebo vs the recommended treatment regimen with intravenous methylprednisolone in moderate to severe thyroid eye disease: a meta-analysis and matching-adjusted indirect comparison. JAMA Ophthalmol 140:328\u2013335. https:\/\/doi.org\/10.1001\/jamaophthalmol.2021.6284","journal-title":"JAMA Ophthalmol"},{"key":"6013_CR38","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/cen.13170","volume":"86","author":"X Ye","year":"2017","unstructured":"Ye X, Bo X, Hu X, Cui H, Lu B, Shao J, Wang J (2017) Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves\u2019 orbitopathy. Clin Endocrinol 86:247\u2013255. https:\/\/doi.org\/10.1111\/cen.13170","journal-title":"Clin Endocrinol"},{"key":"6013_CR39","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/s2213-8587(18)30020-2","volume":"6","author":"GJ Kahaly","year":"2018","unstructured":"Kahaly GJ, Riedl M, K\u00f6nig J, Pitz S, Ponto K, Diana T, Kampmann E, Kolbe E, Eckstein A, Moeller LC, F\u00fchrer D, Salvi M, Curro N, Campi I, Covelli D, Leo M, Marin\u00f2 M, Menconi F, Marcocci C, Bartalena L, Perros P, Wiersinga WM (2018) Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol 6:287\u2013298. https:\/\/doi.org\/10.1016\/s2213-8587(18)30020-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6013_CR40","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/eje-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marin\u00f2 M, Vaidya B, Wiersinga WM (2021) The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol 185:G43-g67. https:\/\/doi.org\/10.1530\/eje-21-0479","journal-title":"Eur J Endocrinol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06013-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-023-06013-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06013-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T09:03:56Z","timestamp":1690275836000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-023-06013-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,21]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["6013"],"URL":"https:\/\/doi.org\/10.1007\/s00417-023-06013-4","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,21]]},"assertion":[{"value":"30 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that the study was approved by the Institutional Review Board of the Samsung Medical Center and certify that the study was performed in accordance with the ethical standards of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}